Management of Intermediate-Risk Prostate Cancer

Risk Stratification and Implications

A Gleason score of 4+3=7 places the patient in the intermediate-risk category for prostate cancer according to established guidelines from the American Urological Association and the European Association of Urology 2, 1
The predominant pattern 4 (in 4+3) indicates a more aggressive disease than 3+4=7, with potentially higher risk of progression compared to lower Gleason scores, as reported by the American Joint Committee on Cancer 3
A low Decipher score is a favorable genomic biomarker that suggests a lower risk of metastasis despite the intermediate-risk Gleason score classification, according to the National Comprehensive Cancer Network 4, 1

For intermediate-risk prostate cancer with Gleason 4+3, external beam radiation therapy should be delivered using conformal techniques to a minimum target dose of 70-79 Gy given in 1.8-2.0 Gy fractions, as recommended by the American Society for Radiation Oncology 3, 5
Treatment options for this patient include external beam radiation therapy alone with dose escalation to 78-79 Gy, or external beam radiation therapy with short-course (6 months) androgen deprivation therapy, as suggested by the American Urological Association 3, 1

The low Decipher score provides additional prognostic information beyond the Gleason score and suggests a more favorable outcome, according to the National Comprehensive Cancer Network 4, 1
This genomic classifier helps identify patients who may have less aggressive disease despite having intermediate-risk features on standard pathology, as reported by the Journal of the National Comprehensive Cancer Network 4

For this specific combination (Gleason 4+3 with low Decipher score), consider dose-escalated external beam radiation therapy (78-79 Gy) using 3D conformal techniques with at least four fields and a margin of no more than 10mm at the prostatic rectal interface, as recommended by the American Society for Radiation Oncology 3
Short-course (6 months) androgen deprivation therapy may be added, particularly if there are other adverse features such as PSA >10 ng/mL, as suggested by the European Association of Urology 6, 3

After external beam radiotherapy, serum PSA should reach 1 ng/mL within 16 months, as recommended by the American Urological Association 1
Regular follow-up at six-month intervals for five years and annually thereafter is recommended for oncological outcome assessment, as suggested by the American Society for Radiation Oncology 3

Patients should be informed that androgen deprivation therapy with radiation increases adverse effects on sexual function, as reported by the American Urological Association 1
Radiation dose accuracy and escalation provide proven improvements in local tumor control and reduction in late radiation-related complications, as recommended by the American Society for Radiation Oncology 3
Patients with obstructive urinary symptoms may experience exacerbation with radiation therapy and should be evaluated carefully before treatment, as suggested by the American Urological Association 1